(Q36552753)

14 August 2017

1 reference

title

HIV pharmacology: barriers to the eradication of HIV from the CNS. (English)

1 reference

14 August 2017

1 reference

Bryan McGee

1

1 reference

14 August 2017

Nathalie Smith

series ordinal

2

1 reference

14 August 2017

Francesca Aweeka

series ordinal

3

1 reference

14 August 2017

publication date

1 May 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

142-153

1 reference

Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Two phases of HIV RNA decay in CSF during initial days of multidrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Phylodynamic analysis of human immunodeficiency virus type 1 in distinct brain compartments provides a model for the neuropathogenesis of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Penetration of HIV-1 protease inhibitors into CSF and semen

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Antiretroviral drugs and the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

The blood brain barrier in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Inflammatory mediators and modulation of blood-brain barrier permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Barrier mechanisms in the brain, I. Adult brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Anti-HIV drug distribution to the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

21 January 2018

Emerging anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

The penetration of anti-infectives into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

The distribution of the anti-HIV drug, 2'3'-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Clinical implications of CNS penetration of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAW2H-TP5C-NP43-K6BY

10.1310/AW2H-TP5C-NP43-K6BY

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference